362 related articles for article (PubMed ID: 23086187)
1. Emerging patterns and implications of HIV-1 integrase inhibitor resistance.
Geretti AM; Armenia D; Ceccherini-Silberstein F
Curr Opin Infect Dis; 2012 Dec; 25(6):677-86. PubMed ID: 23086187
[TBL] [Abstract][Full Text] [Related]
2. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
3. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
Oliveira M; Ibanescu RI; Pham HT; Brenner B; Mesplède T; Wainberg MA
AIDS; 2016 Sep; 30(15):2267-73. PubMed ID: 27367488
[TBL] [Abstract][Full Text] [Related]
4. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
5. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
6. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
[TBL] [Abstract][Full Text] [Related]
9. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
12. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
[TBL] [Abstract][Full Text] [Related]
13. Resistance to HIV integrase inhibitors.
Mesplède T; Quashie PK; Wainberg MA
Curr Opin HIV AIDS; 2012 Sep; 7(5):401-8. PubMed ID: 22789986
[TBL] [Abstract][Full Text] [Related]
14. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
15. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
16. HIV drug resistance against strand transfer integrase inhibitors.
Anstett K; Brenner B; Mesplede T; Wainberg MA
Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
[TBL] [Abstract][Full Text] [Related]
18. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
Pendri A; Meanwell NA; Peese KM; Walker MA
Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
[TBL] [Abstract][Full Text] [Related]
19. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
20. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
